Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis.
~1 min read
Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (C-X-C motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10) designed for the treatment of Crohn's disease and ulcerative colitis.
This drug was developed by Bristol-Myers Squibb and Medarex.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).